Evidence map›Paper›PMID 38923860›Full record

ArticleCNS neuroscience & therapeutics2024

Evidences of neurological injury caused by COVID-19 from glioma tissues and glioma organoids.

Huimin Hu, Chen Wang, Rui Tao, Bohan Liu, Dazhao Peng, Yankun Chen, Wei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huimin HuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID 0000-0001-5712-3624
Chen WangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Rui TaoDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Bohan LiuDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Dazhao PengDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Yankun ChenDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Wei ZhangDepartment of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.ORCID 0000-0001-7800-3189

Funding

Beijing Nova Program 20220484029National Natural Science Foundation of China 82341048National Natural Science Foundation of China 82372782Open Research Fund of the National Center for Protein Sciences at Peking University in Beijing KF-202301Public Welfare Development and Reform Pilot Project of Beijing Medical Research Institute JYY2023-2,TaoJiang
6 · The paper itself

Abstract

introductionDespite the extensive neurological symptoms induced by COVID-19 and the identification of SARS-CoV-2 in post-mortem brain samples from COVID-19 patients months after death, the precise mechanisms of SARS-CoV-2 invasion into the central nervous system remain unclear due to the lack of research models.

methodsWe collected glioma tissue samples from glioma patients who had a recent history of COVID-19 and examined the presence of the SARS-CoV-2 spike protein. Subsequently, spatial transcriptomic analyses were conducted on normal brain tissues, glioma tissues, and glioma tissues from glioma patients with recent COVID-19 history. Additionally, single-cell sequencing data from both glioma tissues and glioma organoids were collected and analyzed. Glioma organoids were utilized to evaluate the efficacy of potential COVID-19 blocking agents.

resultsGlioma tissues from glioma patients with recent COVID-19 history exhibited the presence of the SARS-CoV-2 spike protein. Differences between glioma tissues from glioma patients who had a recent history of COVID-19 and healthy brain tissues primarily manifested in neuronal cells. Notably, neuronal cells within glioma tissues of COVID-19 history demonstrated heightened susceptibility to Alzheimer's disease, depression, and synaptic dysfunction, indicative of neuronal aberrations. Expressions of SARS-CoV-2 entry factors were confirmed in both glioma tissues and glioma organoids. Moreover, glioma organoids were susceptible to pseudo-SARS-CoV-2 infection and the infections could be partly blocked by the potential COVID-19 drugs.

conclusionsGliomas had inherent traits that render them susceptible to SARS-CoV-2 infection, leading to their representability of COVID-19 neurological symptoms. This established a biological foundation for the rationality and feasibility of utilization of glioma organoids as research and blocking drug testing model in SARS-CoV-2 infection within the central nervous system.

Indexed as

Brain NeoplasmsCOVID-19GliomaOrganoidsSARS-CoV-2BrainFemaleHumansMaleMiddle AgedSpike Glycoprotein, CoronavirusSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID‐19glioma tissuesorganoidspatial transcriptome

Identifiers

PMID38923860
PMCPMC11199819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.